Mereo BioPharma Group plc (MREO) |
|
1.31 -0.035 (-2.6%)
|
09-28 16:00 |
|
Open: |
1.35 |
Pre. Close: |
1.345 |
|
High:
|
1.36 |
Low:
|
1.29 |
|
Volume:
|
650,538 |
Market Cap:
|
169(M) |
|
|
|
Technical analysis |
as of: 2023-09-28 4:52:06 PM |
|
Short-term rate:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 1.85  One year: 2.06 |
| Support: |
Support1: 1.28 Support2: 1.07 |
| Resistance: |
Resistance1: 1.58 Resistance2: 1.76 |
| Pivot: |
1.4 |
| Moving Average: |
MA(5): 1.33 MA(20): 1.41
MA(100): 1.28 MA(250): 1.05 |
| MACD: |
MACD(12,26): -0.1 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 8.2 %D(3): 7.9 |
| RSI: |
RSI(14): 43.6 |
| 52-week: |
High: 1.76 Low: 0.49 |
| Average Vol(K): |
3-Month: 900 (K) 10-Days: 463 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MREO ] has closed above bottom band by 20.4%. Bollinger Bands are 8.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.36 - 1.37 |
1.37 - 1.37 |
|
Low:
|
1.27 - 1.28 |
1.28 - 1.29 |
|
Close:
|
1.3 - 1.31 |
1.31 - 1.32 |
|
Company Description |
|
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom. |
Headline News |
Thu, 28 Sep 2023
Does Mereo BioPharma Group plc - ADR (MREO) Have What it Takes to be in Your Portfolio Thursday? - InvestorsObserver
Thu, 21 Sep 2023
Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference - Yahoo Finance
Mon, 18 Sep 2023
Where Will Mereo BioPharma Group plc - ADR (MREO) Stock Go Next After It Is Higher By 9.42% in a Week? - InvestorsObserver
Fri, 08 Sep 2023
Needham Reiterates Mereo Biopharma Group Plc - ADR (MREO ... - Nasdaq
Thu, 31 Aug 2023
Mereo Biopharma Group Plc - ADR (MREO) Price Target Increased ... - Nasdaq
Wed, 23 Aug 2023
Is Mereo BioPharma Group plc - ADR (MREO) Stock at the Top of the Biotechnology Industry? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
129 (M) |
| Shares Float |
76 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
51 (%) |
|
Shares Short
|
4,850 (K) |
|
Shares Short P.Month
|
6,200 (K) |
Stock Financials |
|
EPS
|
-0.29 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.46 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-444.3 |
|
Return on Assets (ttm)
|
-21 |
|
Return on Equity (ttm)
|
-41 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0.05 |
|
EBITDA (p.s.)
|
-0.25 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-33 (M) |
|
Levered Free Cash Flow
|
-30 (M) |
Stock Valuations |
|
PE Ratio
|
-4.68 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
2.84 |
|
Price to Sales
|
23.63 |
|
Price to Cash Flow
|
-5.07 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
